Raymond James Financial Comments on TSE:HLS Q3 Earnings

Key Points

• Raymond James Financial has raised its Q3 2025 earnings per share estimate for HLS Therapeutics from ($0.11) to ($0.10), while maintaining a "Moderate Buy" rating and a target price of $6.00.
• The stock of HLS Therapeutics opened at C$5.22, with a market capitalization of C$116.13 million, and shows significant growth potential indicated by future earnings forecasts.
• HLS Therapeutics specializes in acquiring and commercializing branded pharmaceutical products, particularly focusing on treatments for the central nervous system and cardiovascular specialties.

HLS Therapeutics Inc. (TSE:HLS - Free Report) - Equities research analysts at Raymond James Financial raised their Q3 2025 earnings estimates for shares of HLS Therapeutics in a report released on Thursday, August 21st. Raymond James Financial analyst M. Freeman now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their previous forecast of ($0.11). Raymond James Financial has a "Moderate Buy" rating and a $6.00 price objective on the stock. The consensus estimate for HLS Therapeutics' current full-year earnings is ($0.12) per share. Raymond James Financial also issued estimates for HLS Therapeutics' Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at ($0.08) EPS, FY2028 earnings at $0.04 EPS and FY2029 earnings at $0.14 EPS.

HLS Therapeutics Stock Up 0.2%

TSE:HLS traded up C$0.01 on Monday, hitting C$5.36. 5,221 shares of the company's stock were exchanged, compared to its average volume of 12,445. The firm has a 50-day moving average price of C$4.99 and a 200-day moving average price of C$4.64. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01. HLS Therapeutics has a 52 week low of C$3.00 and a 52 week high of C$5.48. The company has a market cap of C$168.27 million, a P/E ratio of -11.17 and a beta of 0.68.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.